富瑞:升融創服務(1516.HK)目標價至30.72港元 維持買入評級
富瑞發表研究報吿指,融創服務(1516.HK)發盈喜,預期去年純利將按年增長逾1.2倍;在撇除上市開支後,估計公司核心利潤增長將逾1.3倍,維持公司為行業首選及買入評級,但將目標價由27.69港元上調至30.72港元,並預期公司潛在獲納入互聯互通及管理層上調盈利指引有望成為股價未來的催化劑。
該行上調公司今、明兩年利潤預測8至9%,分別達13億元及22億元人民幣,即分別按年增長1.1倍及64%,並相信公司在3月業績發佈會上很大機會上調其保守的盈利指引,以適其快速擴張的規模,估計公司2020至22年總管理面積將分別增長165%、70%及46%,達至1.4億、2.37億及3.47億平方米。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.